Efficacy of Gamma Globulins in Children with Kawasaki Disease and Factors Influencing Children's Short-Term Prognosis

Comput Math Methods Med. 2022 Jul 30:2022:5137874. doi: 10.1155/2022/5137874. eCollection 2022.

Abstract

Purpose: To explore and analyze the therapeutic effect of gamma globulins (GG) on Kawasaki disease (KD) in children and the influencing factors of short-term prognosis.

Methods: First, 90 pediatric KD patients admitted between January 2019 and January 2021 were selected and divided into a control group (n = 40) and a research group (n = 50) according to the difference in treatment. In addition to routine treatment and nursing given to both groups, control group was given aspirin (ASA), based on which research group was supplemented with GG therapy. The treatment outcome and adverse events (AEs) of the two cohorts of patients were analyzed and compared, and the influencing factors of children's short-term prognosis were analyzed by logistics multivariate analysis.

Results: Research group had a statistical higher overall response rate than control group, with significantly fewer cases suffering from AEs such as nausea and vomiting, diarrhea, rash, dizziness and headache, and coronary artery injury. On the other hand, logistics multivariate analysis identified that gender, body mass index (BMI), onset time, platelet (PLT), and treatment mode all independently influence the short-term prognosis of children with KD.

Conclusions: GG therapy is effective in treating pediatric KD patients and can effectively prevent AEs. In addition, gender, BMI, onset-to-treatment time, PLT, C-reactive protein (CRP), and treatment methods are independent risk factors for short-term prognosis of children with KD.

MeSH terms

  • C-Reactive Protein / metabolism
  • Child
  • Coronary Artery Disease* / drug therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Mucocutaneous Lymph Node Syndrome* / complications
  • Mucocutaneous Lymph Node Syndrome* / drug therapy
  • Prognosis
  • Retrospective Studies
  • gamma-Globulins / therapeutic use

Substances

  • Immunoglobulins, Intravenous
  • gamma-Globulins
  • C-Reactive Protein